Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/annonc/mdx540 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multimodal Study of Murine Cardiovascular Remodeling: Four-Dimensional Ultrasound and Mass Spectrometry Imaging.
J Vis Exp
January 2025
Mechanical, Aerospace, and Biomedical Engineering, University of Tennessee;
Cardiovascular disease (CVD) is the leading cause of death in the United States. Damage in the cardiovascular system can be due to environmental exposure, trauma, drug toxicity, or numerous other factors. As a result, cardiac tissue and vasculature undergo structural changes and display diminished function.
View Article and Find Full Text PDFA phase II study of anlotinib as first-line maintenance therapy for advanced ovarian cancer.
Anticancer Drugs
January 2025
Oncology Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province.
Article Synopsis
- Anlotinib has demonstrated positive effects in treating platinum-resistant ovarian cancer, but its role as a maintenance therapy after initial treatment was unclear.
- In a phase II clinical trial with 24 patients, those who received anlotinib after responding to chemotherapy had a median progression-free survival of 15.8 months and an overall survival of 43.8 months.
- The study indicated that anlotinib is a safe and effective option for maintenance therapy, showing promise in extending survival for patients with advanced ovarian cancer.
Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study.
J Intensive Med
January 2025
Medical Intensive Care Unit, APHP Saint-Louis University Hospital, Paris, France.
Background: Cancer patients who are exposed to sepsis and had previous chemotherapy may have increased severity. Among chemotherapeutic agents, anthracyclines have been associated with cardiac toxicity. Like other chemotherapeutic agents, they may cause endothelial toxicity.
View Article and Find Full Text PDFProspective Validation of CAR-HEMATOTOX and a simplified version predict Survival in Patients with Large B-Cell Lymphoma treated with anti-CD19 CAR T-cells: data from CART-SIE study.
Transplant Cell Ther
January 2025
Chair of Hematology, University of Milan; Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano.
Background: Anti-CD19 CAR T-cells have revolutionized outcomes in relapsed/refractory large B-cell lymphomas. Long-term follow-up underscored the role of hematological toxicity in non-relapse mortality, largely driven by infections, leading to the development of the CAR-HEMATOTOX (HT) score for predicting neutropenia. The European scientific community (EHA/EBMT) later reached a consensus, defining a new entity: immune effector cell-associated hematotoxicity (ICAHT).
View Article and Find Full Text PDFAn integrated strategy for sequential nitrite removal and methane recovery: Sludge fermentation driven by nitrite reduction.
Water Res X
May 2025
National Engineering Laboratory for Advanced Municipal Wastewater Treatment and Reuse Technology, Engineering Research Center of Beijing, Beijing University of Technology, Beijing 100124, PR China.
Although the treatment of sludge with free nitrous acid can effectively recover short chain fatty acids, the feasibility of sequential nitrite reduction and methane recovery without acidic pH adjustment is still scarcely studied. Therefore, this study aimed to provide insights into the effect of nitrite at different levels on nitrite reduction and methane production. The results showed that the nitrite concentrations of 100, 200, 400 and 800 mg/L were completely reduced in 1, 2, 2 and 4 days, respectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!